CEO David Bunton told us the site, which is the first headquarters of Reprocell Europe – an offshoot of Japan-based Reprocell – will focus on cell and tissue therapies.
“The Centre for Predictive Drug Discovery will be Reprocell’s main centre for the provision of human cell and tissue-based drug discovery services, with clients worldwide,” he said.
“We are aiming to grow our business by offering the most relevant human-based preclinical models in stem cells, 3D tissues and human fresh tissues,” he added.
Bunton said the decision to establish headquarters in Scotland came from Reprocell’s acquisition of UK firms Biopta and Reinnervate, which were brought together to form Reprocell Europe in 2016.
“Scotland has a leading reputation in pharmacology and was the base for Biopta Ltd, which Reprocell acquired in Dec 2015,” Bunton explained.
“The new Centre for Predictive Drug Discovery builds on not only the Biopta human fresh tissue services but also offers stem cell reprogramming and 3D tissue assay services,” he added.
Bunton said the Centre will grow its Glasgow-based workforce and expand operations to focus on the launch on new services.
“We plan to create 15 new jobs (three already in post) over the next two years, boosting our RNA-based stem cell reprogramming services,” he told us.
Reprocell Europe offers stem cell, human tissue and 3D cell culture-based products and services to Europe, the Middle East and Africa.